Soligenix, Inc. — Form 10-Q Summary
Reporting period: Quarter and nine months ended September 30, 2014. The filing was signed November 10, 2014. Soligenix is a development-stage biopharmaceutical company with BioTherapeutics and Vaccines/BioDefense segments; its revenue is primarily from government contracts and grants.
Financial results and position
| Metric | Three months 2014 | Three months 2013 | Nine months 2014 | Nine months 2013 |
|---|---|---|---|---|
| Revenue | $2.788 million | $0.312 million | $5.117 million | $1.845 million |
| Gross profit | $0.678 million | $0.067 million | $1.343 million | $0.328 million |
| Operating loss | $5.141 million | $1.861 million | $8.427 million | $5.704 million |
| Net loss | $4.350 million | $6.560 million | $8.630 million | $11.052 million |
| Basic and diluted loss per share | $0.21 | $0.34 | $0.43 | $0.78 |
- Revenue included $2.195 million of contract revenue and $0.593 million of grant revenue in the quarter; nine-month revenue included $3.753 million of contract revenue and $1.363 million of grant revenue. Most of the increase was attributed to progress on OrbeShield government contracts.
- Gross margin was approximately 24% for the quarter and 26% for the nine-month period. Contract reimbursement and management fees contributed to higher gross profit.
- Cash and cash equivalents were $4.210 million at September 30, 2014, down $1.646 million from year-end 2013. Net cash used in operations was $2.098 million for the nine months, versus $3.164 million in 2013; financing provided $0.499 million, while investing used $0.047 million.
- Current liabilities were $10.549 million, including a $7.429 million warrant liability. Management reported working capital of $2.634 million after excluding that non-cash warrant liability; on the balance-sheet basis including it, current liabilities exceeded current assets. The filing reports no debt balance.
- Total assets were $6.273 million and shareholders’ deficiency was $4.276 million. Common shares outstanding increased from 19.626 million at December 31, 2013 to 22.050 million at September 30, 2014.
Material changes and unusual items
- Nine-month revenue rose 177% year over year, while net loss narrowed 22%. Quarterly net loss narrowed 34%, substantially affected by warrant fair-value changes: a $0.791 million gain in Q3 2014 versus a $4.700 million expense in Q3 2013. The nine-month 2014 warrant remeasurement was a $0.204 million expense, compared with a $5.349 million expense in 2013.
- Research and development expense included $4.000 million of acquired in-process R&D for the synthetic hypericin/SGX301 program acquired from Hy Biopharma. Consideration included $250,000 cash and 1,849,113 shares valued at $3.750 million. Because the acquired assets had no alternative future use, the amount was expensed.
- The company issued shares through its Lincoln Park equity facility, to vendors and a collaboration partner, and in connection with the Hy Biopharma acquisition. Additional milestone consideration of up to $10 million under that acquisition may be payable in restricted shares, subject to a 19.99% share cap.
Outlook, management commentary, and risks
- Management said available cash, government funding, the Lincoln Park facility and expected New Jersey NOL-sale proceeds should fund working capital and capital expenditures for at least 12 months. It cited up to $53.3 million of active contract and grant funding remaining and approximately $9.5 million available under a $10 million equity facility through October 2016. These amounts are not equivalent to unrestricted cash and depend on program funding, facility use or other conditions.
- For the next 12 months, the company estimated R&D spending of approximately $13.4 million before grant reimbursements and contract/grant revenue of approximately $9.0 million, primarily offsetting Vaccines/BioDefense R&D costs.
- Development plans included a Phase 3 SGX301 trial planned for the first half of 2015; Phase 2 SGX942 results expected in the first half of 2015; and Phase 2/3 SGX203 and Phase 1/2 RiVax studies planned for 2015. These timelines and plans are forward-looking and subject to funding, regulatory and clinical risks.
- Other exposures include early-stage product development and regulatory uncertainty, dependence on government grants and contracts, potential need for additional equity financing and dilution, warrant-liability valuation volatility, and contingent milestone or royalty payments. The filing cites up to $7 million of potential Intrexon milestones and up to $10 million of Hy Biopharma milestones, payable only upon specified success conditions. Contractual obligations listed for 2014–2018 total $396,000, excluding contingent milestones.
- Management reported disclosure controls were effective and no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Whether government contract and grant funding is awarded, continued, and collected on expected schedules, and whether the stated $53.3 million remaining funding is available for the company’s planned uses.
- Cash burn versus management’s 12-month runway assessment, including actual availability and use of the Lincoln Park equity facility and New Jersey NOL-sale proceeds.
- Clinical-trial progress, funding, and results for SGX301, SGX942, SGX203, RiVax and OrbeShield, including whether projected milestones and timelines remain achievable.
- Potential dilution from outstanding warrants, equity-line sales, registered resale shares and contingent Hy Biopharma milestone shares.
- The warrant liability’s valuation and the effect of future share-price movements on reported earnings or losses.